×
About 3,480 results

ALLMedicine™ Subdural Hematoma Center

Research & Reviews  1,218 results

Assessing the accuracy of the International Classification of Disease (ICD) framework i...
https://doi.org/10.1016/j.surge.2023.02.001
The Surgeon : Journal of the Royal Colleges of Surgeons O... Yordanov S, Khan S et. al.

Mar 27th, 2023 - Chronic subdural hematoma (CSDH) is one of the commonest neurosurgical pathologies with an increasing incidence. Observational studies of routine care have demonstrated high perioperative morbidity and approximately 10% mortality at one year. The ...

The Finnish Study of Intraoperative Irrigation Versus Drain Alone After Evacuation of Chronic Subdural Hematoma (FINISH)
https://clinicaltrials.gov/ct2/show/NCT04203550

Mar 22nd, 2023 - FINISH-trial is a prospective, randomized, controlled, parallel group non-inferiority trial comparing single burr-hole evacuation of chronic subdural hematoma (CSDH) with intraoperative irrigation (IR) and evacuation of CSDH without irrigation (N-...

Exhaustive Drainage Versus Fixed-time Drainage for Chronic Subdural Hematoma After One-burr Hole Craniostomy
https://clinicaltrials.gov/ct2/show/NCT04573387

Mar 21st, 2023 - Chronic subdural hematomas (CSDHs) are one of the most common neurosurgical conditions. The goal of surgery is to alleviate symptoms and minimize the risk of symptomatic recurrences. The standard surgical technique includes burr-hole craniostomy, ...

Embolization of the Middle Meningeal Artery With ONYX™ Liquid Embolic System for Subacute and Chronic Subdural Hematoma
https://clinicaltrials.gov/ct2/show/NCT04402632

Mar 20th, 2023 - The purpose of this study is to evaluate the safety and efficacy of embolization of the middle meningeal artery (MMA) using the Onyx™ Liquid Embolic System (LES) for treatment of symptomatic subacute or chronic subdural hematoma (SDH)

Development and validation of a recurrent prediction model for patients with unilateral...
https://doi.org/10.1016/j.clineuro.2023.107678
Clinical Neurology and Neurosurgery; Takei J, Inomata T et. al.

Mar 19th, 2023 - Approximately 10 % of patients with chronic subdural hematoma (CSDH) undergo reoperation after initial surgery. This study aimed to develop a predictive model for the recurrence of unilateral CSDH at initial surgery without hematoma volumetric ana...

see more →

Drugs  3 results see all →

Clinicaltrials.gov  84 results

The Finnish Study of Intraoperative Irrigation Versus Drain Alone After Evacuation of Chronic Subdural Hematoma (FINISH)
https://clinicaltrials.gov/ct2/show/NCT04203550

Mar 22nd, 2023 - FINISH-trial is a prospective, randomized, controlled, parallel group non-inferiority trial comparing single burr-hole evacuation of chronic subdural hematoma (CSDH) with intraoperative irrigation (IR) and evacuation of CSDH without irrigation (N-...

Exhaustive Drainage Versus Fixed-time Drainage for Chronic Subdural Hematoma After One-burr Hole Craniostomy
https://clinicaltrials.gov/ct2/show/NCT04573387

Mar 21st, 2023 - Chronic subdural hematomas (CSDHs) are one of the most common neurosurgical conditions. The goal of surgery is to alleviate symptoms and minimize the risk of symptomatic recurrences. The standard surgical technique includes burr-hole craniostomy, ...

Embolization of the Middle Meningeal Artery With ONYX™ Liquid Embolic System for Subacute and Chronic Subdural Hematoma
https://clinicaltrials.gov/ct2/show/NCT04402632

Mar 20th, 2023 - The purpose of this study is to evaluate the safety and efficacy of embolization of the middle meningeal artery (MMA) using the Onyx™ Liquid Embolic System (LES) for treatment of symptomatic subacute or chronic subdural hematoma (SDH)

Defining the Operating Characteristics of NIRS in the Diagnosis of Pediatric Traumatic Intracranial Hemorrhage
https://clinicaltrials.gov/ct2/show/NCT03905031

Mar 6th, 2023 - Patients that present to Dayton Children's Hospital with a head CT order for suspected TBI will be approached for enrollment. An alert will notify study personnel as CT scans are ordered. The goal is to obtain NIRS data within four-hours before or...

Patient Registry for Patients With Chronic Subdural Hematoma
https://clinicaltrials.gov/ct2/show/NCT04170582

Mar 2nd, 2023 - Chronic subdural hematoma (cSDH) is a frequent disease in- predominantly - elderly patients often caused by minor trauma to the bridging veins eventually leading to a collection of old blood in the subdural space over time. Besides age of the pati...

see more →

News  84 results

New, Simple Technique for Chronic Subdural Hematoma Cuts Recurrence by 50%
https://www.medscape.com/viewarticle/984462

Nov 22nd, 2022 - Using irrigation warmed to body temperature during burr hole evacuation for chronic subdural hematoma (cSDH) cuts the risk for recurrence by more than half compared and should become the standard of care, new research suggests. Results from the mu...

BCMA and CD3 T-cell–Engaging Bispecific Antibody Shows Promise in R/R Multiple Myeloma
https://www.onclive.com/view/bcma-and-cd3-t-cell-engaging-bispecific-antibody-shows-promise-in-r-r-multiple-myeloma

Nov 1st, 2022 - ABBV-383 was effective and well tolerated at all administered doses in patients with relapsed/refractory multiple myeloma, according to safety and efficacy results from an ongoing first-in-human, phase 1 dose-escalation/-expansion study (NCT039337...

Cediranib Plus Olaparib Elicits rPFS Benefit in Metastatic Castration-Resistant Prostate Cancer
https://www.onclive.com/view/cediranib-plus-olaparib-elicits-rpfs-benefit-in-metastatic-castration-resistant-prostate-cancer

Oct 24th, 2022 - The combination of cediranib and olaparib (Lynparza) significantly improved radiographic progression-free survival (rPFS) compared with olaparib monotherapy in patients with metastatic castration-resistant prostate cancer (mCRPC), according to fin...

Bispecific Antibody ABBV-383 Looks to Fill Unmet Need in Heavily Pretreated Multiple Myeloma
https://www.onclive.com/view/bispecific-antibody-abbv-383-looks-to-fill-unmet-need-in-heavily-pretreated-multiple-myeloma

Aug 28th, 2022 - Promising safety and efficacy results were observed with the novel bispecific antibody ABBV-383 in patients with heavily pretreated relapsed or refractory multiple myeloma, according to updated results from a phase 1 trial (NCT03933735) presented ...

Helping patients move forward following traumatic brain injury
https://www.mdedge.com/familymedicine/article/255453/preventive-care/helping-patients-move-forward-following-traumatic
MDedge Family Medicine; Elizabeth A. Imbesi, PhD, ABPP

Jun 15th, 2022 - THE CASE Declan M*, a 42-year-old man, presents as a new patient for general medical care. One year ago, he sustained a severe frontal traumatic brain injury (TBI) when he was hit by a car while crossing a street.

see more →

Patient Education  3 results see all →